A van Oosterom
Overview
Explore the profile of A van Oosterom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
1724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pietersma F, van Oosterom A, Ran L, Schuurman R, Meijer E, de Jonge N, et al.
Transpl Immunol
. 2012 Feb;
27(1):48-51.
PMID: 22342937
EBV seronegative recipients of cardiac transplantation are at risk for development of post transplant lymphoproliferative disease following primary EBV infection due to the ongoing treatment with immunosuppressive drugs. Here we...
2.
Oostendorp T, van Dessel P, Coronel R, Belterman C, Linnenbank A, van Schie I, et al.
Neth Heart J
. 2011 Oct;
19(11):488-91.
PMID: 22006012
Determining electrical activation of the heart in a noninvasive way is one of the challenges in cardiac electrophysiology. The ECG provides some, but limited information about the electrical status of...
3.
Ghysel C, Ponette D, Oyen R, van Oosterom A, van Poppel H
BJU Int
. 2009 Jan;
92 Suppl 3:e2.
PMID: 19125460
No abstract available.
4.
de Jonge M, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, et al.
Eur J Cancer
. 2006 Jul;
42(12):1768-74.
PMID: 16815702
Purpose: Halofuginone (tempostatin) is a synthetic derivative of a quinazolinone alkaloid showing anti-angiogenic, anti-metastatic and anti-proliferative effects in preclinical studies. The objectives of this phase I study were to assess...
5.
Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, et al.
Ann Oncol
. 2006 Apr;
17(7):1158-65.
PMID: 16600980
Background: Oral administration of irinotecan (CPT-11) should allow sustained exposure to the drug without the inconvenience of intravenous delivery and with fewer side-effects. Patients And Methods: The present phase I...
6.
Ahmed B, Landuyt W, Griffioen A, van Oosterom A, Van Den Bogaert W, Lambin P
Anticancer Res
. 2006 Feb;
26(1A):307-10.
PMID: 16475711
Background: The study aimed at evaluating the potential benefit from a combination of fractionated ionising radiation with the vascular-targeting compound combretastatin A-4 phosphate (CA-4-P). Materials And Methods: Syngenic rat rhabdomyosarcoma...
7.
Blay J, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos A, et al.
Ann Oncol
. 2005 Mar;
16(4):566-78.
PMID: 15781488
Background: The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international consensus meeting were to describe the optimal management...
8.
Nevelsteen I, De Wever I, Stas M, Devroe H, Dumez H, van Oosterom A
Acta Chir Belg
. 2005 Jan;
104(6):683-9.
PMID: 15663275
Gastrointestinal stromal tumours (GIST), previously classified as smooth muscle tumours, are the most common mesenchymal tumours of the digestive tract. Since the discovery of KIT (CD 117) expression, these tumours...
9.
Le Cesne A, Blay J, Judson I, van Oosterom A, Verweij J, Radford J, et al.
J Clin Oncol
. 2005 Jan;
23(3):576-84.
PMID: 15659504
Purpose: This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m(2) as a 24-hour continuous infusion...
10.
van Oosterom A
J Electrocardiol
. 2004 Nov;
37 Suppl:193-7.
PMID: 15534840
This contribution discusses the dominant T wave, a concept providing an overall view on the repolarization currents of the ventricular myocardium. The dominant T wave is a weighted mean of...